Survival after curative treatment of muscle-invasive bladder cancer

Acta Oncologica

Volumn 35, Issue SUPPL. 8, 1996, Pages 59-65

  Fosså, Sophie D ^a,c   Aass, Nina ^a   Ous, Sigurd ^a   Wæhre, Hakon ^a   Ilner, Kari ^a   Hannisdal, Einar ^b  

^a Department of Medical Oncology and Radiotherapy ^*

^b Clinical Research Office

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 0030425415     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609098521     Document Type: Article

References (33)

1. UICC (Union Internationale contre le Cancer 1987). TNM classification of malignant tumours, 4th ed. Geneva: UICC, Springer-Verlag, Berlin Heidelberg, 1987: 133-5.
2. Fosså SD, Ous S, Langmark F, Espetveit S. Survival and pattern of care in bladder cancer. Scand J Urol Nephrol 1992; 26: 131-8.
3. Fosså SD, Wæhre H, Aass N, Jacobsen A-B, Olsen DR, Ous S. Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. Cancer 1993; 72: 3036-43.
4. Wæhre H, Ous S, Klevmark B, et al. A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer. Cancer 1993; 72: 3044-51.
5. Malmström P-U, Rintala E, Wahlqvist R, Hellström P, Hellsten S, Hannisdal E. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy. Nordic Cystectomy Trial I. J Urol, in press, 1996.
6. Hall RR for MRC Advanced Bladder Cancer Group Working Party, EORTC GU Group, NCI Canada, Norwegian Bladder Cancer Group, Australian Bladder Cancer Study Group, Club Urologica Espanol de Tratamiento and Fin Bladder. Neo-adjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer. First analysis of MRC/ EORTC Intercontinental Trial. Proceedings ASCO 1996; 244.
7. Bloom HJG, Hendry WF, Wallace DM, Skeet RG. Treatment of T3 bladder cancer: Controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Second report and review (for the Clinical Trials Group, Institute of Urology). Br J Urol 1982; 54: 136-51.
8. Herr HW. Preoperative irradiation with and without chemotherapy as adjuvant to radical cystectomy. Urology 1985; 25: 127-34.
9. Anderström C, Johansson S, Nilsson S, Unsgaard B, Wahlqvist L. A randomized study of preoperative irradiation with cystectomy or cystectomy alone for invasive bladder carcinoma. Eur Urol 1983; 9: 142-7.
10. Parsons JT, Million RR. Planned preoperative irradiation in the management of clinical stage B2-C (T3) bladder carcinoma. Int J Radiat Oncol Biol Phys 1988; 14: 797-810.
11. Crawford DE, Das S, Smith JA. Preoperative radiation therapy in the treatment of bladder cancer. Urol Clin North Am 1987; 14: 781-7.
12. Mameghan H, Fisher RJ, Watt WH, et al. The management of invasive transitional cell carcinoma of the bladder. Cancer 1992; 69: 2771-8.
13. Malmström P-U, Rintala E, Wahlqvist R, Hellstrōm P, Hellsten S, Hannisdal E. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy. J Urol 1996; in press.
14. Pollack A, Zagars GK, Dinney CP, Swanson DS, von Eschenbach AC. Preoperative radiotherapy for muscle-invasive bladder carcinoma. Cancer 1994; 74: 2819-27.
15. Pagano F, Bassi P, Galetti TP, Meneghini A, Milani C, Artibani W, Garbeglio A. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991; 145: 45-50.
16. Zincke H, Patterson DE, Utz DC, Benson RC. Pelvic lymphadenectomy and radical cystectomy for transitional cell carcinoma of the bladder with pelvic nodal disease. Br J Urol 1985; 57: 156-9.
17. Smith SA, Whitmore WF Jr. Regional lymph node metastasis from bladder cancer. J Urol 1981; 126: 591-3.
18. Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 1986; 7: 299-310.
19. Goodman GB, Hislop TG, Elwood JM, Balfour J. Conservation of bladder function in patients with invasive bladder cancer treated by definitive irradiation and selected cystectomy. Int J Radiat Oncol Biol Phys 1981; 7: 569-75.
20. Shipley WU, Rose MA, Perrone TL, Mannix CM, Heney NM, Prout GR Jr. Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. J Urol 1985; 134: 679-83.
21. Pollack A, Zagars GK, Swanson DS. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys 1994; 30: 267-77.
22. Matsumoto K, Kakisoe T, Mikuriya S, Tanaka T, Kondo I, Umegaki Y. Clinical evaluation of intraoperative radiotherapy for carcinoma of the urinary bladder. Cancer 1981; 47: 509-13.
23. van der Werf-Messing B. Cancer of the urinary bladder treated by interstitial radium implant. Int J Radiat Oncol Biol Phys 1978; 4: 373-8.
24. Eidsmyr F, Anderson L, Esposti PL, Littbrand B, Nilsson B. Irradiation therapy with multiple small fractions per day in urinary bladder cancer. Radiother Oncol 1985; 4: 197-203.
25. Fosså SD, Ous S, Berner Aa. The clinical significance of the 'palpable mass' in patients with muscle-infiltrating bladder cancer undergoing cystectomy after pre-operative radiotherapy. Br J Urol 1991; 67: 54-60.
26. Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, et al. Cisplatin, Methotrexate, and Vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group Study. J Clin Oncol 1985; 3: 1463-70.
27. Sternberg C, Yagoda A, Scher HI, et al. Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-58.
28. Splinter TWA, Scher HI, Denis L, et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. J Urol 1992; 147: 606-8.
29. Schultz PK, Herr HW, Zhang Z-F, et al. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Ciln Oncol 1994; 12: 1394-1401.
30. Dunst J, Sauer R, Schrott KM, et al. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys 1994; 30: 261-6.
31. Roth BJ. Preliminary experience with paclitaxel in advanced bladder cancer. Sem Oncol 1995; 22: 1-5.
32. Moore MJ, Tannock I, Ernst S, Huan S, Murray N. Gemcitabine demonstrates promising activity as a single agent in the treatment of metastatic transitional cell carcinoma. Proceedings ASCO 1996; 250.
33. Stöckle M, Meyenberg W, Wellek S, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992; 148: 302-7.